Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clin Cardiol ; 37(6): 343-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24700276

ABSTRACT

BACKGROUND: The clinical significance of mildly elevated troponins in patients presenting to the emergency room (ER) with atrial fibrillation (AF) is not well understood. HYPOTHESIS: We hypothesized that mildly elevated troponin in these patients is associated with adverse cardiovascular outcomes. METHODS: In a multi-center, retrospective study, 662 patients with AF were divided into 3 groups based on troponin levels: group 1, mildly elevated; group 2, normal; and group 3, troponin not measured. Primary outcome was the combined endpoint of all-cause mortality and myocardial infarction (MI) at one year. RESULTS: Levels of TnI were measured in 503 (76%) patients. They were elevated in 220 patients (33%, group 1; mean, 0.56 ng/mL), normal in 283 patients (43%, group 2), and not measured in 159 patients (24%, group 3). Significantly more cardiac testing was done at index hospitalization in group 1 (50%) compared with groups 2 and 3 (28% and 29%, P ≤ 0.001) and in the following year (29%, vs 20% and 17%, P = 0.02). Group 1 had more positive tests (62%) compared with groups 2 and 3 (25% and 43%, P ≤ 0.001). Group 1 had a significantly higher occurrence of the primary endpoint (22%, vs 10% and 15%, P = 0.002), driven primarily by a higher incidence of MI in group 1 (7%, vs 1% and 2%, P = 0.001). CONCLUSIONS: Troponin levels are routinely checked in a majority of patients presenting to the emergency department with AF. Even mildly elevated TnI is associated with a greater incidence of coronary artery disease on diagnostic testing and a higher 1-year incidence of MI.


Subject(s)
Atrial Fibrillation/blood , Myocardial Infarction/diagnosis , Troponin I/blood , Adult , Aged , Aged, 80 and over , Biomarkers , Emergency Service, Hospital , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , Young Adult
2.
Respiration ; 83(3): 198-208, 2012.
Article in English | MEDLINE | ID: mdl-21576924

ABSTRACT

BACKGROUND: Eosinophilic pleural effusion (EPE) is defined by an eosinophil count of ≥10% in the pleural fluid and often caused by air or blood in the pleural space. The diagnostic significance of EPEs is still a matter of debate. OBJECTIVE: The objective of this study was to systematically review the medical literature to evaluate the diagnostic significance of EPEs. METHODS: Electronic databases were searched from 1950 to April 2010 to perform a meta-analysis. Data were extracted using standardized forms, and pooled odds ratios with 95% confidence intervals were calculated. A logistic regression analysis was also performed to evaluate the association between the pleural eosinophil counts and the likelihood of underlying causes of EPEs. RESULTS: We identified a total of 687 cases of EPE. The most common cause of EPEs was malignancy (26%) followed by idiopathic (25%) and parapneumonic (13%) effusions. The likelihood of malignancy or tuberculosis was somehow lower in EPEs than in non-EPEs, but the differences were not statistically significant. The prevalence of malignancy was significantly lower in the group of patients that required a pathologic confirmation (21 vs. 30%; p = 0.01). The likelihood of malignancy was inversely correlated with the pleural fluid eosinophil counts. The likelihood of idiopathic effusion was significantly higher in EPEs than in non-EPEs. CONCLUSIONS: Malignancy was the most common cause of EPEs. EPEs appeared to be a negative predictor of malignancy when a pleural fluid eosinophil count was extremely high. EPEs were more likely to be idiopathic as compared with non-EPEs.


Subject(s)
Eosinophilia/epidemiology , Pleural Effusion/epidemiology , Collagen Diseases/epidemiology , Eosinophilia/diagnosis , Humans , Pleural Effusion/diagnosis , Pleural Effusion, Malignant/epidemiology , Prevalence , Pulmonary Embolism/epidemiology , Tuberculosis/epidemiology , Vascular Diseases/epidemiology
3.
Adv Ther ; 28(9): 728-47, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21833701

ABSTRACT

Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bronchitis/drug therapy , Pneumonia, Ventilator-Associated/drug therapy , Tracheitis/drug therapy , Ventilators, Mechanical/adverse effects , Administration, Inhalation , Aerosols , Anti-Bacterial Agents/pharmacokinetics , Bronchitis/etiology , Bronchitis/microbiology , Cross Infection/drug therapy , Humans , Intubation, Intratracheal/adverse effects , Lung/metabolism , Nebulizers and Vaporizers , Pneumonia, Ventilator-Associated/microbiology , Tracheitis/etiology , Tracheitis/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...